In a new study, a team of researchers from Inserm, University Hospital Lille, and Université de Lille at the Lille Neuroscience and Cognition laboratory has opened up interesting avenues to improve the prognosis of preterm infants.
By conducting research into congenital hypogonadotropic hypogonadism, scientists have discovered the key role that nitric oxide synthase (NOS1) plays and the therapeutic potential of the neurotransmitter that it synthesizes—nitric oxide—in reducing the risk of long-term complications in the event of prematurity. Their findings are described in Science Translational Medicine. A clinical trial has also been launched at the Lille University Hospital in partnership with a hospital in Athens (Greece) in order to go further and measure the effect of nitric oxide on premature infants.
More information about this research paper is available here.